Solid Biosciences to Participate at Cantor's Virtual Muscular Dystrophy Symposium

Stock Information for SeaSpine Holdings Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About SeaSpine Holdings Corporation

Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results
Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
Solid Biosciences to Participate at Upcoming Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.